Gene Therapy Market by Vector Type (Viral Vector and Non-viral Vector), Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others), and Applications (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases): Global Opportunity Analysis and Industry Forecast, 2017 - 2023
- ALL2449055
- 232 Pages
- February 2018
- Healthcare
Gene therapy is an attractive area for drug development with the goal to treat the cause of the disease instead of just relieving the symptoms. Gene therapy helps repair, repress, or replace dysfunctional genes with the aim of reestablishing normal function. Some gene mutations result in these proteins not being made correctly and can lead to genetic disorders. Gene therapy involves incorporation of an artificial or a modified gene using modified viral vectors that help deliver the gene at intended site of action or even kill the cell that may cause the disease. Gene therapy requires very few doses of medication to cure the disease. The global gene therapy market was valued at $584 million in 2016, and is estimated to reach $4,402 million by 2023, registering a CAGR of 33.3% from 2017 to 2023.
Genes are composed of DNA that contains necessary information for making proteins that are vital for the human body to function optimally. For certain disorders where known genetic mutations lead to deficient or non-functional protein production, gene therapy can fix the underlying defect and provide a path to produce the functional protein. Gene therapy is intended to introduce healthy gene into damaged cells to counteract for abnormal genes or to make a protein of interest. Mutated gene causes missing of the important protein, with the help of gene therapy normal copy of that missing or faulty protein can be introduced to restore the function of the protein.
Increasing gene therapy innovations for cardiovascular and rare diseases treatment and ethical acceptance of gene therapy for cancer treatment are the major factors that drive the market growth. Rising focus on development of gene therapy treatment for rare diseases is a result of intensifying competition among market players to consolidate their position in the industry. In addition, increase in government support and rise in prevalence of cancer can fuel the growth of the gene therapy market. However, high cost associated with the treatment and unwanted immune responses are expected to hamper the market growth.
Based on vector type, it is categorized into viral vector and non-viral vector. Among the vector type, viral vector is the largest contributor toward the market growth. Non-viral vector is anticipated to be a lucrative market due to the technological advancement of these vectors with positive results for these therapies during the preclinical and clinical trials for the treatment of various diseases.
Based on application, it is categorized into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and other diseases. viral Oncological disorders is the largest contributor toward the market growth owing to the high prevalence of cancer worldwide and availability of regulatory approved gene therapy for cancer.
Based on region, the gene therapy market is divided into North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in the gene therapy market in 2016, and is expected to retain its dominance throughout the forecast period due to high prevalence and rising incidence rates of non-Hodgkin lymphoma.
The key players operating in the global gene therapy market include Novartis, Kite Pharma, Inc., GlaxoSmithKline PLC, Spark Therapeutics Inc., Bluebird bio Inc., Genethon, Transgene SA, Applied Genetic Technologies Corporation, Oxford BioMedica, and NewLink Genetics Corp.
KEY BENEFITS FOR STAKEHOLDERS
This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
Market estimations are based on comprehensive analysis of the key developments in the industry.
The global market is comprehensively analyzed with respect to type, method, technology, end user, and region.
In-depth analysis based on geography assists in understanding the regional market to assist in strategic business planning.
The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Vector Type
- Viral vector
- Retroviruses
- Lentiviruses
- Adenoviruses
- Adeno Associated Virus
- Herpes Simplex Virus
- Poxvirus
- Vaccinia Virus
- Others
- Non-viral vector
- Naked/Plasmid Vectors
- Gene Gun
- Electroporation
- Lipofection
- Others
By Gene Type
- Antigen
- Cytokine
- Tumor Suppressor
- Suicide
- Deficiency
- Growth factors
- Receptors
- Others
By Application
- Oncological Disorders
- Rare Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Infectious disease
- Other Diseases
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Republic of South Africa
- Rest of LAMEA
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.2.2.1. Top winning strategies, by year, 2015-2017*
3.2.2.2. Top winning strategies, by development, 2015-2017* (%)
3.2.2.3. Top winning strategies, by company, 2015-2017*
3.3. Top player positioning, 2016
3.4. Porters five forces analysis
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. High investment for R&D activities pertaining to gene therapy
3.5.1.2. Increase in prevalence of cancer
3.5.1.3. Growth in awareness regarding gene therapy
3.5.2. Restraints
3.5.2.1. High cost associated with gene therapies
3.5.2.2. Unwanted immune responses
3.5.3. Opportunity
3.5.3.1. Untapped potential for emerging markets
CHAPTER 4: GENE THERAPY MARKET, BY VECTOR TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Viral vectors
4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Market Analysis by country
4.2.5. Adenovirus
4.2.6. Lentivirus
4.2.7. Retrovirus
4.2.8. Adeno-associated virus
4.2.9. Herpes simplex virus
4.2.10. Poxvirus
4.2.11. Vaccinia virus
4.2.12. Others
4.3. Nonviral techniques
4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Market Analysis by country
4.3.5. Naked plasmid vector
4.3.6. Gene gun
4.3.7. Electroporation
4.3.8. Lipofection
4.3.9. Others
CHAPTER 5: GENE THERAPY MARKET, BY GENE TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Antigen
5.2.1. Market size and forecast
5.2.2. Market size and forecast by country
5.3. Cytokine
5.3.1. Market size and forecast
5.3.2. Market Analysis, by country
5.4. Tumor suppressor
5.4.1. Market size and forecast
5.4.2. Market Analysis, by country
5.5. Suicide
5.5.1. Market size and forecast
5.5.2. Market Analysis, by country
5.6. Deficiency
5.6.1. Market size and forecast
5.6.2. Market Analysis, by country
5.7. Growth factors
5.7.1. Market size and forecast
5.7.2. Market Analysis, by country
5.8. Receptors
5.8.1. Market size and forecast
5.8.2. Market Analysis, by country
5.9. Others
5.9.1. Market size and forecast
5.9.2. Market Analysis, by country
CHAPTER 6: GENE THERAPY MARKET, BY APPLICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Oncological disorders
6.2.1. Market size and forecast
6.2.2. Market Analysis, by country
6.3. Rare diseases
6.3.1. Market size and forecast
6.3.2. Market Analysis, by country
6.4. Cardiovascular diseases
6.4.1. Market size and forecast
6.4.2. Market Analysis, by country
6.5. Neurological disorders
6.5.1. Market size and forecast
6.5.2. Market Analysis, by country
6.6. Infectious diseases
6.6.1. Market size and forecast
6.6.2. Market Analysis, by country
6.7. Other diseases
6.7.1. Market size and forecast
6.7.2. Market Analysis, by country
CHAPTER 7: GENE THERAPY MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast, by country
7.2.4. Market size and forecast, by vector type
7.2.5. Market size and forecast, by gene type
7.2.6. Market size and forecast, by application
7.2.6.1. U.S. market size and forecast, by vector type
7.2.6.2. U.S. market size and forecast, by gene type
7.2.6.3. U.S. market size and forecast, by application
7.2.6.4. Canada market size and forecast, by vector type
7.2.6.5. Canada market size and forecast, by gene type
7.2.6.6. Canada market size and forecast, by application
7.2.6.7. Mexico market size and forecast, by vector type
7.2.6.8. Mexico market size and forecast, by gene type
7.2.6.9. Mexico market size and forecast, by application
7.3. Europe
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast, by country
7.3.4. Market size and forecast, by vector type
7.3.5. Market size and forecast, by gene type
7.3.6. Market size and forecast, by application
7.3.6.1. Germany market size and forecast, by vector type
7.3.6.2. Germany market size and forecast, by gene type
7.3.6.3. Germany market size and forecast, by application
7.3.6.4. France market size and forecast, by vector type
7.3.6.5. France market size and forecast, by gene type
7.3.6.6. France market size and forecast, by application
7.3.6.7. UK market size and forecast, by vector type
7.3.6.8. UK market size and forecast, by gene type
7.3.6.9. UK market size and forecast, by application
7.3.6.10. Italy market size and forecast, by vector type
7.3.6.11. Italy market size and forecast, by gene type
7.3.6.12. Italy market size and forecast, by application
7.3.6.13. Spain market size and forecast, by vector type
7.3.6.14. Spain market size and forecast, by gene type
7.3.6.15. Spain market size and forecast, by application
7.3.6.16. Rest of Europe market size and forecast, by vector type
7.3.6.17. Rest of Europe market size and forecast, by gene type
7.3.6.18. Rest of Europe market size and forecast, by application
7.4. Asia-Pacific
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast, by country
7.4.4. Market size and forecast, by vector type
7.4.5. Market size and forecast, by gene type
7.4.6. Market size and forecast, by application
7.4.6.1. Japan market size and forecast, by vector type
7.4.6.2. Japan market size and forecast, by gene type
7.4.6.3. Japan market size and forecast, by application
7.4.6.4. China market size and forecast, by vector type
7.4.6.5. China market size and forecast, by gene type
7.4.6.6. China market size and forecast, by application
7.4.6.7. India market size and forecast, by vector type
7.4.6.8. India market size and forecast, by gene type
7.4.6.9. India market size and forecast, by application
7.4.6.10. South Korea market size and forecast, by vector type
7.4.6.11. South Korea market size and forecast, by gene type
7.4.6.12. South Korea market size and forecast, by application
7.4.6.13. Rest of Asia-Pacific market size and forecast, by vector type
7.4.6.14. Rest of Asia-Pacific market size and forecast, by gene type
7.4.6.15. Rest of Asia-Pacific market size and forecast, by application
7.5. LAMEA
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast, by country
7.5.4. Market size and forecast, by vector type
7.5.5. Market size and forecast, by gene type
7.5.6. Market size and forecast, by application
7.5.6.1. Brazil market size and forecast, by vector type
7.5.6.2. Brazil market size and forecast, by gene type
7.5.6.3. Brazil market size and forecast, by application
7.5.6.4. South Africa market size and forecast, by vector type
7.5.6.5. South Africa market size and forecast, by gene type
7.5.6.6. South Africa market size and forecast, by application
7.5.6.7. Rest of LAMEA market size and forecast, by vector type
7.5.6.8. Rest of LAMEA market size and forecast, by gene type
7.5.6.9. Rest of LAMEA market size and forecast, by application
CHAPTER 8: COMPANY PROFILE
8.1. Adaptimmune Therapeutics Plc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. Biocancell Ltd.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.3. Bluebird Bio, Inc.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance
8.3.5. Key strategic moves and developments
8.4. Celgene Corporation
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance
8.4.5. Key strategic moves and developments
8.5. Gilead Sciences, Inc.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. Glaxosmithkline Plc
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. Merck & Co., Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. Novartis AG
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. Oncogenex Pharmaceuticals, Inc.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance
8.9.5. Key strategic moves and developments
8.10. Spark Therapeutics, Inc.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 02. GLOBAL GENE THERAPY MARKET FOR VIRAL VECTORS, BY REGION, 2016-2023 ($MILLION)
TABLE 03. GLOBAL GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2016-2023 ($MILLION)
TABLE 04. GENE THERAPY MARKET FOR NONVIRAL VECTORS, BY REGION, 2016-2023 ($MILLION)
TABLE 05. GLOBAL GENE THERAPY MARKET FOR NONVIRAL VECTORS, BY TYPE, 2016-2023 ($MILLION)
TABLE 06. GLOBAL GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 07. ANTIGEN GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 08. CYTOKINE GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 09. TUMOR SUPPRESSOR GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 10. SUICIDE GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 11. DEFICIENCY GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 12. GROWTH FACTORS GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 13. RECEPTORS GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 14. GENE THERAPY MARKET FOR OTHER GENE TYPE, BY REGION, 2016-2023 ($MILLION)
TABLE 15. GLOBAL GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 16. GENE THERAPY MARKET FOR ONCOLOGICAL DISORDERS, BY REGION, 2016-2023 ($MILLION)
TABLE 17. GENE THERAPY MARKET FOR RARE DISEASES, BY REGION, 2016-2023 ($MILLION)
TABLE 18. GENE THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2016-2023 ($MILLION)
TABLE 19. GENE THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2016-2023 ($MILLION)
TABLE 20. GENE THERAPY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2016-2023 ($MILLION)
TABLE 21. GENE THERAPY MARKET FOR OTHER DISEASES, BY REGION, 2016-2023 ($MILLION)
TABLE 22. GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 23. NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 24. NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 25. NORTH AMERICA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 26. NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 27. U.S. GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 28. U.S. GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 29. U.S. GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 30. CANADA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 31. CANADA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 32. CANADA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 33. MEXICO GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 34. MEXICO GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 35. MEXICO GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 36. EUROPE GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 37. EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 38. EUROPE GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 39. EUROPE GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 40. GERMANY GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 41. GERMANY GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 42. GERMANY GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 43. FRANCE GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 44. FRANCE GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 45. FRANCE GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 46. UK GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 47. UK GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 48. UK GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 49. ITALY GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 50. ITALY GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 51. ITALY GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 52. SPAIN GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 53. SPAIN GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 54. SPAIN GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 55. REST OF EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 56. REST OF EUROPE GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 57. REST OF EUROPE GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 58. ASIA-PACIFIC GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 59. ASIA-PACIFIC GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 60. ASIA-PACIFIC GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 61. ASIA-PACIFIC GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 62. JAPAN GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 63. JAPAN GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 64. JAPAN GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 65. CHINA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 66. CHINA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 67. CHINA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 68. INDIA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 69. INDIA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 70. INDIA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 71. SOUTH KOREA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 72. SOUTH KOREA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 73. SOUTH KOREA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 74. REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 75. REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 76. REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 77. LAMEA GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 78. LAMEA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 79. LAMEA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 80. LAMEA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 81. BRAZIL GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 82. BRAZIL GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 83. BRAZIL GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 84. SOUTH AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 85. SOUTH AFRICA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 86. SOUTH AFRICA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 87. REST OF LAMEA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 88. REST OF LAMEA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 89. REST OF LAMEA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 90. ADAPTIMMUNE THERAPEUTICS PLC.: COMPANY SNAPSHOT
TABLE 91. ADAPTIMMUNE THERAPEUTICS PLC.: BUSINESS UNIT
TABLE 92. ADAPTIMMUNE THERAPEUTICS PLC.: PRODUCT PORTFOLIO
TABLE 93. BIOCANCELL LTD.: COMPANY SNAPSHOT
TABLE 94. BIOCANCELL LTD.: PRODUCT CATEGORY
TABLE 95. BIOCANCELL LTD.: PRODUCT PORTFOLIO
TABLE 96. BLUEBIRD BIO, INC.: COMPANY SNAPSHOT
TABLE 97. BLUEBIRD BIO, INC.: PRODUCT CATEGORY
TABLE 98. CELGENE CORPORATION: COMPANY SNAPSHOT
TABLE 99. CELGENE CORPORATION: OPERATING SEGMENTS
TABLE 100. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
TABLE 101. GILEAD SCIENCES, INC.: OPERATING SEGMENTS
TABLE 102. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 103. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
TABLE 104. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 105. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 106. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 107. MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 108. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 109. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 110. NOVARTIS AG : OPERATING DIVISION
TABLE 111. NOVARTIS AG : PRODUCT PORTFOLIO
TABLE 112. ONCOGENEX PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 113. ONCOGENEX PHARMACEUTICALS, INC.: OPERATING SEGMENTS
TABLE 114. SPARK THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 115. SPARK THERAPEUTICS, INC.: PRODUCT CATEGORY
TABLE 116. SPARK THERAPEUTICS, INC.: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. GLOBAL GENE THERAPY MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS: BY GENE TYPE, 2016
FIGURE 03. TOP PLAYER POSITIONING, 2016
FIGURE 04. BARGAINING POWER OF BUYERS
FIGURE 05. BARGAINING POWER OF SUPPLIERS
FIGURE 06. THREAT OF NEW ENTRANTS
FIGURE 07. THREAT OF SUBSTITUTION
FIGURE 08. COMPETITIVE RIVALRY
FIGURE 09. RESTRAINTS AND DRIVERS: GLOBAL GENE THERAPY MARKET
FIGURE 10. COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR VIRAL VECTORS, 2016 & 2023 ($MILLION)
FIGURE 11. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR NON-VIRAL VECTORS, 2016 & 2023 (%)
FIGURE 12. COMPARATIVE REGIONAL ANALYSIS OF ANTIGEN GENE THERAPY MARKET, 2016 & 2023 (%)
FIGURE 13. COMPARATIVE REGIONAL ANALYSIS OF CYTOKINE GENE THERAPY MARKET, 2016 & 2023 (%)
FIGURE 14. COMPARATIVE REGIONAL ANALYSIS OF TUMOR SUPPRESSOR GENE THERAPY MARKET, 2016 & 2023 (%)
FIGURE 15. COMPARATIVE REGIONAL ANALYSIS OF SUICIDE GENE THERAPY MARKET, 2016 & 2023 (%)
FIGURE 16. COMPARATIVE REGIONAL ANALYSIS OF DEFICIENCY GENE THERAPY MARKET, 2016 & 2023 (%)
FIGURE 17. COMPARATIVE REGIONAL ANALYSIS OF GROWTH FACTORS GENE THERAPY MARKET, 2016 & 2023 (%)
FIGURE 18. COMPARATIVE REGIONAL ANALYSIS OF RECEPTORS GENE THERAPY MARKET, 2016 & 2023 (%)
FIGURE 19. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR OTHER GENE TYPE, 2016 & 2023 (%)
FIGURE 20. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR ONCOLOGICAL DISORDERS, 2016 & 2023 (%)
FIGURE 21. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR RARE DISEASES, 2016 & 2023 (%)
FIGURE 22. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR CARDIOVASCULAR DISEASES, 2016 & 2023 (%)
FIGURE 23. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR NEUROLOGICAL DISORDERS, 2016 & 2023 (%)
FIGURE 24. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR INFECTIOUS DISEASES, 2016 & 2023 (%)
FIGURE 25. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR OTHER DISEASES, 2016 & 2023 (%)
FIGURE 26. ADAPTIMMUNE THERAPEUTICS PLC.: REVENUE, 2014-2016 ($MILLION)
FIGURE 27. BLUEBIRD BIO, INC.: REVENUE, 2014-2016 ($MILLION)
FIGURE 28. CELGENE CORPORATION: REVENUE, 2014-2016 ($MILLION)
FIGURE 29. CELGENE CORPORATION: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 30. CELGENE CORPORATION: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 31. GILEAD SCIENCES, INC.: REVENUE, 2014-2016 ($MILLION)
FIGURE 32. GILEAD SCIENCES, INC.: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 33. GLAXOSMITHKLINE PLC.: REVENUE, 2014-2016 ($MILLION)
FIGURE 34. GLAXOSMITHKLINE PLC.: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 35. GLAXOSMITHKLINE PLC.: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 36. MERCK & CO., INC.: REVENUE, 2014-2016 ($MILLION)
FIGURE 37. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 38. MERCK & CO., INC.: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 39. NOVARTIS AG: REVENUE, 2015-2017 ($MILLION)
FIGURE 40. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 41. NOVARTIS AG: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 42. ONCOGENEX PHARMACEUTICALS, INC.: REVENUE, 2014-2016 ($MILLION)
FIGURE 43. SPARK THERAPEUTICS, INC.: REVENUE, 2014-2016 ($MILLION)
Similar Reports
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
- Publish Date: February 26, 2018
- $5370
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
- Publish Date: May 29, 2018
- $5370
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...
- Publish Date: May 1, 2016
- $5370
